To support the Antithrombotic Therapy to Ameliorate Complications of COVID-19 (ATTACC) trial. This international, multicenter, adaptive, open-label randomized clinical trial will examine the impact of therapeutic anticoagulation in comparison to standard venous thromboprophylaxis on the risk of intubation and death in hospitalized patients with COVID-19.
- Funded by Emergent Ventures Fast Grants
- Total publications:0 publications
Grant number: unknown
Grant search
Key facts
Disease
COVID-19Start & end year
N/AFunder
Emergent Ventures Fast GrantsPrincipal Investigator
Dr. Ewan GoligherResearch Location
CanadaLead Research Institution
University Health Network and University of ManitobaResearch Priority Alignment
N/A
Research Category
Clinical characterisation and managementResearch Subcategory
Supportive care, processes of care and managementSpecial Interest Tags
N/AStudy Type
ClinicalClinical Trial Details
Randomized Controlled TrialBroad Policy Alignment
PendingAge Group
UnspecifiedVulnerable Population
UnspecifiedOccupations of Interest
Unspecified
Abstract
To support the Antithrombotic Therapy to Ameliorate Complications of COVID-19 (ATTACC) trial. This international, multicenter, adaptive, open-label randomized clinical trial will examine the impact of therapeutic anticoagulation in comparison to standard venous thromboprophylaxis on the risk of intubation and death in hospitalized patients with COVID-19.